ERBB2 and breast cancer: This smart way of delivering chemotherapy is currently used in HER2-positive BC with the advent of trastuzumab-emtansine (T-DM1) (von Minckwitz et al., 2019), and trastuzumab deruxtecan (Cortés et al., 2022; Modi et al., 2022) and in TNBC with Sacituzumab govitecan (Bardia et al., 2021), having different linkers and payloads.